EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Development and validation of BCG vaccine‐induced novel granulomatous liver injury preclinical animal model

Swati Sharma, Abhishek Moudgil, Jyoti Grewal, Pankaj Khatri, Vishal Sharma, Madhumita Premkumar, Amanjit Bal, Dibyajyoti Banerjee, Amol N Patil iD

Animal Models and Experimental Medicine · 2025

DOI: 10.1002/ame2.12559 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Animal Models and Experimental Medicine, 2025. Verfasst von Swati Sharma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: BCG Vaccine, Disease Models, Animal, Granuloma, Chemical and Drug Induced Liver Injury. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Developing a granulomatous liver injury preclinical model may pave the way to understanding hepatic‐TB (tuberculosis) and autoimmune granulomatous liver diseases. Antitubercular (ATT) and other drugs' metabolism in the presence of a specific type of liver injury is not well understood. The present study aimed to establish a preclinical model of granulomatous hepatitis by using the BCG (Bacillus Calmette‐Guérin) vaccine, further studying it in the presence of ATT dosing, and analyze the pharmacokinetics of isoniazid, rifampicin, and their respective primary metabolites.

Methods

We used 56 rats in seven equal groups. Group I functioned as a normal control (NC) receiving normal saline only. Groups II–IV received intravenous injections of low‐, medium‐, and high‐dose BCG vaccine daily for 21 days. Groups V, VI, and VII received isoniazid (H) alone, rifampicin (R) alone, and isoniazid + rifampicin(HR) for a subsequent 15 days in addition to high dose BCG for the first 21 days, respectively. Liver function tests (LFT) were monitored on days 0, 21, 28, and 36. Rats were sacrificed later for oxidative stress and histopathological examination.

Results

The study observed BCG dose‐specific LFT derangements in groups II–IV compared to group I on day 21 ( p < 0.05). Isoniazid, rifampicin, and combination intervention groups demonstrated normalization of the BCG‐led LFT changes. Histology and oxidative stress parameters confirmed model development and biochemical changes. Isoniazid area under the curve (AUC) showed a reduction of 16.9% in BCG + HR group in comparison to the BCG + H group ( p = 0.01). Des‐acetyl‐rifampicin AUC and maximum‐concentration value demonstrated a significant rise in BCG + HR group in comparison to the BCG + R group ( p = 0.001).

Conclusion

A novel preclinical model of granulomatous liver injury was developed using the BCG vaccine strain and validated with ATT response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BCG VaccineDisease Models, AnimalGranulomaChemical and Drug Induced Liver InjuryAnimalsRifampinIsoniazidRatsAntitubercular AgentsMaleLiverLiver Function TestsOxidative Stress

Stichwörter der Autor:innen

acetyl‐isoniazidanimal modelclearancedesacetyl‐rifampicingranulomatous hepatitishalf‐lifehepatic tuberculosisisoniazidpharmacokineticspreclinicalrifampicinthe area under the curve

Substanzen

BCG VaccineRifampinIsoniazidAntitubercular Agents

Autor:innen und Institutionen

  • Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Clinical Medicine and Medical Oncology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Gastroenterology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
  • Department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

ORCID-Profile: Amol N Patil

Zitieren

APA

Sharma, S., Moudgil, A., Grewal, J., Khatri, P., Sharma, V., Premkumar, M., Bal, A., Banerjee, D., & Patil, A. N. (2025). Development and validation of BCG vaccine‐induced novel granulomatous liver injury preclinical animal model. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12559

Vancouver

Sharma S, Moudgil A, Grewal J, Khatri P, Sharma V, Premkumar M, et al. Development and validation of BCG vaccine‐induced novel granulomatous liver injury preclinical animal model. Animal Models and Experimental Medicine. 2025. doi:10.1002/ame2.12559

BibTeX
@article{Sharma2025,
  author = {Sharma, Swati and Moudgil, Abhishek and Grewal, Jyoti and Khatri, Pankaj and Sharma, Vishal and Premkumar, Madhumita and Bal, Amanjit and Banerjee, Dibyajyoti and Patil, Amol N},
  title = {Development and validation of BCG vaccine‐induced novel granulomatous liver injury preclinical animal model},
  journal = {Animal Models and Experimental Medicine},
  year = {2025},
  doi = {10.1002/ame2.12559}
}
Kostenlos starten →